Type II CTRCD has also been observed in other cancer treatments, such as anti-HER2-targeted therapies (the monoclonal antibodies pertuzumab and trastuzumab emtansine), and the tyrosine kinase inhibitor (TKI) lapatinib [6,8]. This evidence concerns the gene ERBB2 and cancer.